CEACAM3 and pancreatic adenocarcinoma: In pancreatic adenocarcinoma, integrin αvβ6 and/or CEA were expressed in 99 % of the patients and 64 % of the cases expressed both integrin αvβ6 and CEA, suggesting that the combination of both targets would be a promising approach for tumor-specific imaging.